Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma

Exclusion Criteria

• •Subjects with central nervous system involvement.
• •Subjects with concomitant second malignancy (except adequately treated non-melanoma skin cancer, ductal carcinoma in-situ, superficial bladder cancer, prostate cancer or in situ cervical cancer) are excluded unless a complete remission was achieved at least 3 years prior to study entry and no additional therapy is required or anticipated.
• •A serious uncontrolled medical disorder or active infection which impairs the ability of the subject to receive protocol therapy or whose control is jeopardized by the complication of this therapy.
• •Prior organ allograft or allogeneic bone marrow transplantation.
• •Positive for HIV (1/2) or known acquired immunodeficiency syndrome.
• •Positive for hepatitis B Surface Ag, or antibody to hepatitis B core ag, or hepatitis C antibody or hepatitis C RNA in serum.
• •Ejection fraction less than 45% in subjects with prior anthracycline therapy (measurement of ejection fraction is mandatory).
• •Corrected QT interval (QTc) prolongation of more than 500.
• •Women of reproductive age who are unwilling or unable to use an acceptable method to minimize the risk of pregnancy for the entire study period and for at least 18 weeks after the last dose of pentamidine.
• •Women who are pregnant or breast-feeding.
• •Women with a positive pregnancy test (serum assay) on enrollment or prior to pentamidine administration.
• •Sexually active men not using birth control if their partners are women of reproductive age.
• •Prisoner or subjects who are involuntarily incarcerated.
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to pentamidine and/or ifosfamide, carboplatin and etoposide.
• •No investigational or commercial agents or therapies other than those specified by the protocol may be administered with the intent to treat the patient's malignancy.